{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:8364"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:8364","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Preclinical development of adoptive T-cell immunotherapy for EBV-associated diseases using third-party donors","abstract":"A significant number of patients requiring adoptive T-cell therapy (ATCT) need to resort to third party donors; we aimed to find ways to optimise ATCT from third party donors in EBV-associated diseases. Firstly, we evaluated the T-cell response to 29 EBV-restricted peptides in a cohort of 100 healthy donors. For each peptide we found at least one high-responding donor. Also, we compared the efficacy of different separation techniques. These results support the setting up of a registry of third party donors, to provide fresh EBV-specific T cells for ATCT. Secondly, we investigated the mechanisms generating T memory stem cells (T\\(_S\\)\\(_C\\)\\(_M\\)), which are considered most suitable for ATCT. We demonstrated that homeostatic cytokines revert recently differentiated CD8\\(^+\\) memory T cells from cord blood (CB) to cells with a T\\(_N\\)-like phenotype (T\\(_N\\)\\(_r\\)\\(_e\\)\\(_v\\)) and T\\(_S\\)\\(_C\\)\\(_M\\)-like characteristics. Finally, we compared phenotype and function of CD8\\(^+\\) T cells from peripheral blood and CB, after transduction of an EBV-specific TCR. Transduction efficiency, growth kinetics and cytolytic activity were comparable. However, TCR-transduced CB T cells showed less differentiated phenotype, increased multi-cytokine expression, and lacked expression of the senescence marker CD57. These data suggest that survival of engineered T cells in vivo is likely to be improved by using cells from CB.","abstract_html":"A significant number of patients requiring adoptive T-cell therapy (ATCT) need to resort to third party donors; we aimed to find ways to optimise ATCT from third party donors in EBV-associated diseases. Firstly, we evaluated the T-cell response to 29 EBV-restricted peptides in a cohort of 100 healthy donors. For each peptide we found at least one high-responding donor. Also, we compared the efficacy of different separation techniques. These results support the setting up of a registry of third party donors, to provide fresh EBV-specific T cells for ATCT. Secondly, we investigated the mechanisms generating T memory stem cells (T<span class=\"etd-inline-math\"><sub>S</sub></span><span class=\"etd-inline-math\"><sub>C</sub></span><span class=\"etd-inline-math\"><sub>M</sub></span>), which are considered most suitable for ATCT. We demonstrated that homeostatic cytokines revert recently differentiated CD8<span class=\"etd-inline-math\"><sup>+</sup></span> memory T cells from cord blood (CB) to cells with a T<span class=\"etd-inline-math\"><sub>N</sub></span>-like phenotype (T<span class=\"etd-inline-math\"><sub>N</sub></span><span class=\"etd-inline-math\"><sub>r</sub></span><span class=\"etd-inline-math\"><sub>e</sub></span><span class=\"etd-inline-math\"><sub>v</sub></span>) and T<span class=\"etd-inline-math\"><sub>S</sub></span><span class=\"etd-inline-math\"><sub>C</sub></span><span class=\"etd-inline-math\"><sub>M</sub></span>-like characteristics. Finally, we compared phenotype and function of CD8<span class=\"etd-inline-math\"><sup>+</sup></span> T cells from peripheral blood and CB, after transduction of an EBV-specific TCR. Transduction efficiency, growth kinetics and cytolytic activity were comparable. However, TCR-transduced CB T cells showed less differentiated phenotype, increased multi-cytokine expression, and lacked expression of the senescence marker CD57. These data suggest that survival of engineered T cells in vivo is likely to be improved by using cells from CB.","abstract_has_math":true,"creators":["Frumento, Guido"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-07","date_published":"2018-07","updated_at":"2026-11-19T09:30:10Z","subjects":["RA0421 Public health. Hygiene. Preventive Medicine","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/8364/1/Frumento2018PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A8364","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Frumento, Guido"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-07"]},{"key":"dc:date.issued","label":"Date","values":["2018-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/8364/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RA0421 Public health. Hygiene. Preventive Medicine","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/8364/1/Frumento2018PhD.pdf","http://etheses.bham.ac.uk//id/eprint/8364/2/Decl_IS_Frumento2018PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["A significant number of patients requiring adoptive T-cell therapy (ATCT) need to resort to third party donors; we aimed to find ways to optimise ATCT from third party donors in EBV-associated diseases. Firstly, we evaluated the T-cell response to 29 EBV-restricted peptides in a cohort of 100 healthy donors. For each peptide we found at least one high-responding donor. Also, we compared the efficacy of different separation techniques. These results support the setting up of a registry of third party donors, to provide fresh EBV-specific T cells for ATCT. Secondly, we investigated the mechanisms generating T memory stem cells (T\\(_S\\)\\(_C\\)\\(_M\\)), which are considered most suitable for ATCT. We demonstrated that homeostatic cytokines revert recently differentiated CD8\\(^+\\) memory T cells from cord blood (CB) to cells with a T\\(_N\\)-like phenotype (T\\(_N\\)\\(_r\\)\\(_e\\)\\(_v\\)) and T\\(_S\\)\\(_C\\)\\(_M\\)-like characteristics. Finally, we compared phenotype and function of CD8\\(^+\\) T cells from peripheral blood and CB, after transduction of an EBV-specific TCR. Transduction efficiency, growth kinetics and cytolytic activity were comparable. However, TCR-transduced CB T cells showed less differentiated phenotype, increased multi-cytokine expression, and lacked expression of the senescence marker CD57. These data suggest that survival of engineered T cells in vivo is likely to be improved by using cells from CB."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Preclinical development of adoptive T-cell immunotherapy for EBV-associated diseases using third-party donors"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Frumento, Guido"],"dc:date":["2018-07"],"dc:date.issued":["2018-07"],"dc:description.abstract":["A significant number of patients requiring adoptive T-cell therapy (ATCT) need to resort to third party donors; we aimed to find ways to optimise ATCT from third party donors in EBV-associated diseases. Firstly, we evaluated the T-cell response to 29 EBV-restricted peptides in a cohort of 100 healthy donors. For each peptide we found at least one high-responding donor. Also, we compared the efficacy of different separation techniques. These results support the setting up of a registry of third party donors, to provide fresh EBV-specific T cells for ATCT. Secondly, we investigated the mechanisms generating T memory stem cells (T\\(_S\\)\\(_C\\)\\(_M\\)), which are considered most suitable for ATCT. We demonstrated that homeostatic cytokines revert recently differentiated CD8\\(^+\\) memory T cells from cord blood (CB) to cells with a T\\(_N\\)-like phenotype (T\\(_N\\)\\(_r\\)\\(_e\\)\\(_v\\)) and T\\(_S\\)\\(_C\\)\\(_M\\)-like characteristics. Finally, we compared phenotype and function of CD8\\(^+\\) T cells from peripheral blood and CB, after transduction of an EBV-specific TCR. Transduction efficiency, growth kinetics and cytolytic activity were comparable. However, TCR-transduced CB T cells showed less differentiated phenotype, increased multi-cytokine expression, and lacked expression of the senescence marker CD57. These data suggest that survival of engineered T cells in vivo is likely to be improved by using cells from CB."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/8364/1/Frumento2018PhD.pdf","http://etheses.bham.ac.uk//id/eprint/8364/2/Decl_IS_Frumento2018PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/8364/"],"dc:subject":["RA0421 Public health. Hygiene. Preventive Medicine","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Preclinical development of adoptive T-cell immunotherapy for EBV-associated diseases using third-party donors"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:30:10Z"}